CN103387528B - N-甲基-2(2-羟乙基)吡咯烷的拆分方法及应用 - Google Patents
N-甲基-2(2-羟乙基)吡咯烷的拆分方法及应用 Download PDFInfo
- Publication number
- CN103387528B CN103387528B CN201310330986.4A CN201310330986A CN103387528B CN 103387528 B CN103387528 B CN 103387528B CN 201310330986 A CN201310330986 A CN 201310330986A CN 103387528 B CN103387528 B CN 103387528B
- Authority
- CN
- China
- Prior art keywords
- solvent
- methyl
- solution
- hydroxyethyl
- tetramethyleneimine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- FYVMBPXFPFAECB-UHFFFAOYSA-N 2-(1-methylpyrrolidin-2-yl)ethanol Chemical compound CN1CCCC1CCO FYVMBPXFPFAECB-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000243 solution Substances 0.000 claims description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 35
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 17
- 239000012065 filter cake Substances 0.000 claims description 16
- 238000002425 crystallisation Methods 0.000 claims description 15
- 230000008025 crystallization Effects 0.000 claims description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000000967 suction filtration Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000011259 mixed solution Substances 0.000 claims description 9
- BQFCCCIRTOLPEF-UHFFFAOYSA-N chembl1976978 Chemical compound CC1=CC=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 BQFCCCIRTOLPEF-UHFFFAOYSA-N 0.000 claims description 8
- 239000006260 foam Substances 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 7
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 claims description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 239000012044 organic layer Substances 0.000 claims description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000292 calcium oxide Substances 0.000 claims description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000002274 desiccant Substances 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 claims description 2
- 238000010025 steaming Methods 0.000 claims description 2
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 abstract description 29
- 229960002689 clemastine fumarate Drugs 0.000 abstract description 29
- 230000003287 optical effect Effects 0.000 abstract description 22
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 238000003786 synthesis reaction Methods 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 2
- FYVMBPXFPFAECB-SSDOTTSWSA-N 2-[(2r)-1-methylpyrrolidin-2-yl]ethanol Chemical compound CN1CCC[C@@H]1CCO FYVMBPXFPFAECB-SSDOTTSWSA-N 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 40
- 238000001816 cooling Methods 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 230000006837 decompression Effects 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 238000001035 drying Methods 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 229960002881 clemastine Drugs 0.000 description 5
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000006340 racemization Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical class COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 2
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 2
- 230000002052 anaphylactic effect Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310330986.4A CN103387528B (zh) | 2013-08-01 | 2013-08-01 | N-甲基-2(2-羟乙基)吡咯烷的拆分方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310330986.4A CN103387528B (zh) | 2013-08-01 | 2013-08-01 | N-甲基-2(2-羟乙基)吡咯烷的拆分方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103387528A CN103387528A (zh) | 2013-11-13 |
CN103387528B true CN103387528B (zh) | 2014-09-10 |
Family
ID=49531960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310330986.4A Active CN103387528B (zh) | 2013-08-01 | 2013-08-01 | N-甲基-2(2-羟乙基)吡咯烷的拆分方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103387528B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107011228B (zh) * | 2017-05-24 | 2019-08-09 | 浙江诚意药业股份有限公司 | 一种富马酸氯马斯汀的制备方法 |
CN111087337A (zh) * | 2019-11-19 | 2020-05-01 | 山东科源制药股份有限公司 | 一种富马酸氯马斯汀中间体的拆分方法 |
CN111302996A (zh) * | 2020-03-19 | 2020-06-19 | 山东科源制药股份有限公司 | 一种高手性纯度的富马酸氯马斯汀的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5191253A (en) * | 1975-02-05 | 1976-08-10 | Kogakukatsusei 11 mechiru 22 okishechiruupirorijinno seiho | |
HU208670B (en) * | 1991-06-04 | 1993-12-28 | Budapesti Mueszaki Egyetem | Process for separating and clean ing 1-methyl-2-pyrrolidinyl ethanol enenthiomers |
WO2009094457A2 (en) * | 2008-01-22 | 2009-07-30 | Auspex Pharmaceuticals | Substituted benzhydrylethers |
-
2013
- 2013-08-01 CN CN201310330986.4A patent/CN103387528B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5191253A (en) * | 1975-02-05 | 1976-08-10 | Kogakukatsusei 11 mechiru 22 okishechiruupirorijinno seiho | |
HU208670B (en) * | 1991-06-04 | 1993-12-28 | Budapesti Mueszaki Egyetem | Process for separating and clean ing 1-methyl-2-pyrrolidinyl ethanol enenthiomers |
WO2009094457A2 (en) * | 2008-01-22 | 2009-07-30 | Auspex Pharmaceuticals | Substituted benzhydrylethers |
Non-Patent Citations (2)
Title |
---|
MARIA, Acs等.New method of optical activation for racemic bases..《Tetrahedron Letters》.1991,第32卷(第49期),第7325-7328页. |
New method of optical activation for racemic bases.;MARIA, Acs等;《Tetrahedron Letters》;19911202;第32卷(第49期);第7325-7328页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103387528A (zh) | 2013-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104045637B (zh) | 一种阿哌沙班的制备方法 | |
CN105330586B (zh) | 一种阿普斯特的制备方法 | |
CN103387528B (zh) | N-甲基-2(2-羟乙基)吡咯烷的拆分方法及应用 | |
CN104672238B (zh) | 一种利格列汀的制备方法 | |
CN103087019B (zh) | 一种他司美琼的制备方法 | |
CN104803978B (zh) | 一种埃索美拉唑镁的制备方法 | |
CN101531654B (zh) | 一种卢帕他定的制备方法 | |
CN101880270B (zh) | 一种制备1,1-环丙烷二甲醇环亚硫酸酯的方法 | |
CN103183673B (zh) | (s,s)-2,8-二氮杂双环[4,3,0]壬烷的合成方法 | |
CN101747210A (zh) | 制备α-(二正丁氨基甲基)-2,7-二氯-4-芴甲醇及其盐酸盐的方法 | |
CN105524042B (zh) | 一种制备曲格列汀的方法 | |
CN102850347A (zh) | 一种吡唑衍生物或其盐的拆分方法 | |
CN102875544B (zh) | 琥珀酸索非那新的制备工艺 | |
CN104341336A (zh) | 一种合成阿哌沙班重要中间体的新方法 | |
CN101239983A (zh) | 一种(-)-氢溴酸加兰他敏的手性合成方法 | |
CN102363599B (zh) | 一种西他列汀中间体手性拆分方法 | |
CN110143951A (zh) | 一种盐酸帕唑帕尼原料药三聚体杂质的合成方法 | |
CN106008392B (zh) | 一种抗癌药物达沙替尼的中间体的制备方法 | |
CN101486705B (zh) | 一种阿折地平α晶型的制备方法 | |
CN101514163B (zh) | 光学纯西布曲明及其衍生盐的制备工艺 | |
CN105968019A (zh) | 盐酸氯普鲁卡因制备方法 | |
CN111116493B (zh) | 一种制备Apabetalone的方法、中间体及其中间体的制备方法 | |
CN104292293B (zh) | 一种度他雄胺杂质i的制备方法 | |
CN102964233A (zh) | 一种3,5-二氟三氟甲基苯酮的合成方法 | |
CN106117104A (zh) | 一种维格列汀的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Guo Ming Inventor after: Liu Huaizhen Inventor before: Liu Huaizhen |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LIU HUAIZHEN TO: GUO MING LIU HUAIZHEN |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160629 Address after: 252022 north of the Mount Lu, Liaocheng economic and Technological Development Zone, Shandong Patentee after: SHANDONG CHUANCHENG PHARMACEUTICAL CO., LTD. Address before: 250132, Sichuan Province, Ji'nan high tech Zone 15 martyrs mountain road, Sichuan Province, Shandong medicine Patentee before: Liu Huaizhen |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 252000 north head of Lushan Road, Liaocheng Development Zone, Shandong Province Patentee after: Shandong Chuan Cheng Medicine Co.,Ltd. Address before: 252022 north head of Lushan Road, Liaocheng Economic and Technological Development Zone, Shandong Province Patentee before: SHANDONG CHUANCHENG PHARMACEUTICAL Co.,Ltd. |